Picture Berlin Partner Hotspot for Startups 650x80px
Collaboration › Details

Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies


Period Period 2021-01-07
Organisations Partner, 1st Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Partner, 2nd Sirion Biotech GmbH
  Group Sirion Biotech (Group)
Products Product LentiBoost™ technology (lentiviral transduction enhancer)
  Product 2 CAR-T therapy product

Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA.

Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Allogeneic CAR-T cell therapy represent a future-defining shift in simplicity, availability, and cost efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient derived cells, elevates the technology to the level of a realistic off-the-shelf product.

Dr. Christian Thirion, CEO and founder of SIRION explains: “LentiBOOST™ improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells.”

“We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs,” says SVP BD & Licensing, Dr. Sabine Ott.

About SIRION Biotech

SIRION Biotech began its customer business in 2007 in Munich, setting their goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccination development. This meant building novel, all-encompassing viral vector platforms for lenti-, adeno-, and adeno-associated viruses which expedite its partners’ advances in drug, cosmetics, and food industries. To date SIRION has completed over 1500 projects of all sizes, working closely with over 200 independent customer groups from academia and industry.


Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14

Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
(978) 395-5970

BD & Licensing Contact
Sabine Ott, Ph.D., Senior VP Licensing & BD
SIRION Biotech
+49 89-700-96199-13

Record changed: 2021-01-12


Picture [iito] Plain Stupid Simple 650x80px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top